BRII-835 + BRII-179 for Chronic Hepatitis B in 7MM: Market Size, Forecast, and Emerging Insights 2019-2032
April 22, 2024 09:52 ET
|
Research and Markets
Dublin, April 22, 2024 (GLOBE NEWSWIRE) -- The "BRII-835 + BRII-179 Market Size, Forecast, and Emerging Insight - 2032" report has been added to ResearchAndMarkets.com's offering."BRII-835 +...
Bepirovirsen for Chronic Hepatitis B Drug Pipeline Report 2024: 7MM Market Size, Forecast, and Emerging Insights 2019-2032
April 18, 2024 09:20 ET
|
Research and Markets
Dublin, April 18, 2024 (GLOBE NEWSWIRE) -- The "Bepirovirsen Market Size, Forecast, and Emerging Insight - 2032" report has been added to ResearchAndMarkets.com's offering.This report provides...
OnCore Biopharma Licenses Second-Generation Cyclophilin Inhibitors From NeuroVive for the Treatment of Chronic HBV Infection
September 09, 2014 03:00 ET
|
OnCore Biopharma, Inc.
OnCore Secures Exclusive Worldwide Rights to NVP018
NVP018 Will Complement OnCore's Existing Pipeline Directed at Achieving All-Oral Cure for HBV
DOYLESTOWN, Pa., Sept. 9, 2014 (GLOBE NEWSWIRE)...